Felix Health Slashes GLP-1 Costs, Shaking Up Canada's Weight-Loss Market

TORONTO, ON – May 28, 2026 – A seismic shift is underway in Canada's approach to weight management as digital health company Felix Health announced it will offer the high-demand drug Ozempic at 'generic-level pricing.' The move, part of a broader strategy that also includes the newly approved generic semaglutide, is poised to dismantle the significant cost barriers that have kept GLP-1 medications out of reach for many Canadians.

In a move designed to capture a market surging with demand, Felix has set its price for eligible patients at $149 per month. This all-inclusive fee covers the medication—either Ozempic through a partnership with Novo Nordisk's savings program or the generic Apo-Semaglutide—along with free delivery and crucial ongoing clinical support. To further lower the barrier to entry, the company is also waiving its initial $99 clinician visit fee for new patients, a promotion dubbed 'Get Started for Free'. The immediate impact has been explosive, with the platform reporting a staggering 14-fold increase in weight-loss visit requests within the first 24 hours of the announcement.

The Affordability Breakthrough

For years, the high cost of GLP-1 agonists like Ozempic has been the primary obstacle for Canadians seeking medical intervention for weight management, a condition increasingly recognized as a chronic disease. Without coverage from most public and many private insurance plans for weight loss, out-of-pocket costs for Ozempic typically ranged from $200 to over $450 per month, an unsustainable price for the average person.

The financial strain is not just anecdotal. Felix Health’s own data reveals that cost was the single biggest reason for treatment discontinuation over the past year, cited by nearly one in four of its patients who stopped taking semaglutide. This new pricing strategy directly confronts that reality. An Angus Reid survey commissioned by the company late last year highlighted this price sensitivity, finding that while 28% of Canadians with overweight or obesity would consider a GLP-1 at $100 per month, that figure plummeted to just 5% at a $400 price point.

The market’s response to Felix's announcement underscores this pent-up demand. The initial 14x surge in consultation requests was comprised of 62% new patients, indicating a wave of individuals who were previously on the sidelines, likely due to cost. The remaining 38% from existing or returning patients suggests that even those already in the system were quick to seek more affordable options. Crucially, the company reports that this heightened demand has been sustained for nearly a week, proving it was not just a fleeting reaction but a significant market realignment.

A Shifting Market: Generics and Competition

Felix’s strategic move does not exist in a vacuum. It coincides with a pivotal moment for the Canadian pharmaceutical landscape. In May 2026, Health Canada gave the green light to the country’s first generic versions of semaglutide, the active ingredient in Ozempic. Apotex, a Canadian company, began shipping its Apo-Semaglutide, while another version from Dr. Reddy's Laboratories also entered the market. This made Canada the first G7 nation to authorize generic semaglutide, a development made possible by the expiry of key patents.

The arrival of generics has ignited fierce competition, particularly among the growing number of virtual healthcare providers. Competitors like Hims & Hers Canada have also announced plans to offer generic semaglutide at a similar $149 monthly price point. This new, lower price benchmark is forcing a re-evaluation across the board, from telehealth platforms like Maple and Phoenix to traditional brick-and-mortar pharmacies.

While some traditional pharmacies may offer the generic drug for a slightly lower base price—with some patient forums reporting costs under $100 at retailers like Costco—these options typically do not include the integrated services that virtual clinics champion. As Felix Health’s co-founder and CEO, Kyle Zien, noted, “People are moving quickly when the cost barrier comes down. As more GLP-1 options enter the market, patients need to compare the full picture: the monthly cost, what support is included and how care continues after the prescription.”

Beyond the Prescription: The Value of Integrated Care

While the dramatic price reduction has captured headlines, the company is stressing that successful long-term treatment involves far more than just an affordable prescription. “Lower-cost GLP-1 options are good news for patients, especially those who have been paying out of pocket,” said Tracey Phillips, Chief Pharmacy Officer at Felix Health. “But access is about more than price.”

The platform’s all-inclusive model is built around this philosophy. The $149 monthly fee bundles the medication with a comprehensive support system that includes the initial online assessment, clinician review for appropriate prescribing, pharmacy coordination, and automatic refills with free, discreet delivery. Perhaps most importantly, it includes ongoing clinical care to help patients manage dose adjustments and potential side effects, which are common in the initial phases of treatment. This support appears to be heavily utilized; Felix data shows that 71% of its weight-loss patients engage with clinical or pharmacy support within the first 90 days of starting treatment.

This level of oversight is particularly relevant given the regulatory environment. In Canada, Ozempic remains officially approved only for the treatment of Type 2 diabetes. Its widespread use for weight loss is considered "off-label," a practice that places greater responsibility on prescribing clinicians to ensure patient safety and suitability. While Health Canada has approved a higher-dose version of semaglutide called Wegovy specifically for chronic weight management, it is not widely covered by insurance plans. The integrated care model offered by virtual clinics provides a structured framework for managing this off-label use responsibly, guiding patients through a treatment journey that can be complex.

The Patient Response and Future Outlook

The flood of interest in Felix’s new offering is a clear signal that Canadians are ready and willing to embrace medical treatments for obesity when they are made accessible. The sustained patient demand demonstrates a fundamental shift in consumer behavior, moving from passive interest to active pursuit of care now that the primary financial hurdle has been lowered.

This new era of accessibility is expected to accelerate. Health Canada is currently reviewing at least seven other submissions for generic semaglutide. As more competitors enter the market, basic economic principles suggest that prices could fall even further, potentially dropping to as low as 35% of the original brand-name cost once three or more generics are available. This would not only benefit patients paying out-of-pocket but could also encourage more private insurers to add weight-loss medications to their formularies, broadening access even further.

The developments are about more than just a single drug or company. They represent a significant step forward in treating obesity as the chronic disease it is, rather than a matter of lifestyle or willpower. By combining affordability with a robust system of ongoing clinical support, the landscape for weight management in Canada is being fundamentally reshaped, promising a future where effective medical treatments are no longer a luxury for the few, but a viable option for the many.